Compare Sony Group Corp (SONY) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sony Group Corp vs Viatris Inc — how do they compare? Sony Group Corp trades at $24.13 (market cap $136.87B), while Viatris Inc trades at $17.41 (market cap $20.03B). The key difference: Sony Group Corp is far larger — about 6.8× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold Sony Group Corp for 96 Days and Viatris Inc for 57 Days on average.
| SONY | VTRS | |
|---|---|---|
Market Cap | $136.87B | $20.03B |
Volume | 5,364,503 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $30.26 | $18.27 |
52-Week Low | $19.32 | $9.74 |
Typical Hold Time | 96 Days | 57 Days |
Enterprise Value | $134.77B | $32.15B |
Dividend Yield | 0.66% | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sony trades at $24.05, up 2.25% with mixed technical signals and neutral analyst sentiment. The company reported strong Q2 2026 earnings beat but faces profitability challenges with negative net income margin and ROE. Recent news highlights Sony's content strength and legal actions against AI companies for copyright infringement.
Sony presents a mixed investment case with strong cash flow generation and content portfolio offset by near-term profitability concerns. The stock's valuation appears reasonable with P/E of 20.34, but investors should monitor the company's ability to improve margins amid competitive pressures.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
